Filed on behalf of: KVK-Tech, Inc.

By: Jonathan A. Harris (jharris@axinn.com)
James T. Evans (jevans@axinn.com)
Axinn, Veltrop & Harkrider LLP

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
KVK-Tech, Inc. Petitioner
v.
Shire PLC Patent Owner
U.S. Patent No. 8,884,100

DECLARATION OF WILLIAM J. JUSKO, Ph.D.



# **TABLE OF CONTENTS**

I.	Introduction	1
II.	Qualifications	2
III.	Summary of Opinions	5
IV.	The Pharmacokinetic Parameters and Food Effect Recited in Claims 5-12 and 21 Are Inherent to the Three Bead Composition of Claim 1	7
	A. Pharmacokinetic Parameters	8
	B. Food Effect	10
V.	The Delayed Sustained Release Beads of Burnside Example 4 Would Prolong the Therapeutic Efficacy of the Adderall XR® Two-Bead System	12
VI.	The Dosage Range Recited in Claims 22-30 Is Obvious for the Composition Recited in Claim 1	15
VII.	Conclusion	18



I, William J. Jusko, Ph.D., declare as follows:

### I. <u>INTRODUCTION</u>

- 1. I have been retained by KVK-Tech, Inc. as an independent expert consultant in this proceeding before the United States Patent and Trademark Office. Although I am being compensated at my normal consulting rate for the time I spend on this matter, no part of my compensation is dependent on the outcome of this proceeding, and I have no other interest in this proceeding.
- 2. I understand that this proceeding involves U.S. Patent No. 8,884,100 ("the '100 patent"), the application for which was filed on May 12, 2006, as U.S. Patent Application No. 11/383,066 ("the '066 application"), and issued on September 30, 2014. I further understand that the '100 patent is assigned on its face to Shire LLC ("Patent Owner").
- 3. I understand that the claims of the '100 patent recite, among other things, a pharmaceutical composition comprising pharmaceutically active mixed amphetamine salts in three beads: (1) immediate release beads; (2) delayed pulsed release beads; and (3) delayed sustained release beads. I refer to this composition as a three-bead composition.
- 4. I have been asked to consider whether, from a pharmacokinetics perspective, the pharmacokinetic properties recited in claims 5-12 of the '100



patent and the lack of food effect in claim 21 are inherent in the three-bead composition of claim 1.

- 5. I have also been asked to opine on whether any of the beads in Burnside Examples 1-4 could provide the prolonged drug release needed to augment Adderall XR®.
- 6. Finally, I was also asked to opine on whether the dosages recited in claims 22-30 of the '100 patent are doses a POSA would use in the routine dose optimization of the composition in claim 1 of the '100 patent. My opinions are set forth below.

### II. QUALIFICATIONS

- 7. I am a SUNY Distinguished Professor at the State University of New York at Buffalo in the Department of Pharmaceutical Sciences. I was Chair of the Department of Pharmaceutical Sciences during 2001 2016 and have been Director of the Center of Excellence in Pharmacokinetics and Pharmacodynamics since 2005. My primary area of expertise is in pharmaceutical sciences, particularly pharmacokinetics and pharmacodynamics.
- 8. I received a B.S. in Pharmacy from the State University of New York at Buffalo in 1965. During my undergraduate studies and after receiving my Bachelor's degree, I worked as a pharmacist, at Children's Hospital of Buffalo and then at Soby's Pharmacy in Buffalo.



- 9. I earned my Ph.D. in pharmaceutical sciences with an emphasis on pharmacokinetics from the State University of New York at Buffalo in 1970. Following my doctoral studies, I became Assistant Professor of Pharmacology at Boston University School of Medicine and served as a Clinical Pharmacologist at the Boston Veterans Administration Hospital.
- an Assistant Professor of Pharmaceutics and Director of the Clinical

  Pharmacokinetics Laboratory at Millard Fillmore Hospital and have remained a

  professor at the University ever since. I have taught a wide variety of courses

  during that time, including those that cover the pharmacokinetics and

  pharmacodynamics of various types of drugs. For over 20 years, I have given

  post-graduate courses in which professionals from the industry and FDA come to

  Buffalo for instruction in pharmacokinetics and pharmacodynamics. I also provide

  such instruction to industry professionals at their companies as well as other

  locations throughout the world.
- 11. During my 50-year career as a researcher in the field of pharmaceutical sciences, I have served as a consultant for the National Institutes of Health (NIH), United States Food and Drug Administration (FDA), and various pharmaceutical companies, such as Amgen, Genentech Inc., Pfizer Inc., Roche, and Wyeth (now Pfizer), among others.



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

#### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

